| Literature DB >> 36006944 |
Zhuang Chen1, Ming Li1, Chenghua Yin1, Youbo Fang2, Ye Zhu1, Jing Feng1.
Abstract
AIMS: The purpose of this study was to investigate the effects of cardiac rehabilitation (CR) on elderly patients with Chronic heart failure (CHF) by literature search and meta-analysis.Entities:
Mesh:
Year: 2022 PMID: 36006944 PMCID: PMC9409506 DOI: 10.1371/journal.pone.0273251
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.752
Fig 1Literature search process.
Outcome indicators.
| Study | Study design | Age(years) (E/C) | Sample size (E/C) | Interventions (E/C) | Follow-up (M) | Outcome indicators |
|---|---|---|---|---|---|---|
| LUO YL 2015 [ | RCT | 80.7±7.8/80±7.4 | 35/37 | MT+CR/MT | 3–12 | LVEF;LVDD;MLHFQ;BNP;NYHA; |
| XIAO YL 2021 [ | RCT | 66.78±4.43/65.27±4.37 | 35/35 | MT+CR/MT | 3 | Total effective rate of nursing; |
| SHEN F 2019 [ | RCT | 67.5±11.5/68.4±10.3 | 50/50 | MT+CR/MT | 3 | 6MWT;PRO-BNP |
| LIU LP 2020 [ | RCT | 75.21±2.22/75.79±2.11 | 25/25 | MT+CR/MT | 6 | MLHFQ;ESES;6MWT;PRO-BNP |
| LIAO JX 2020 [ | RCT | 67.42±5.63/66.50±5.74 | 52/52 | MT+CR/MT | 3 | MLHFQ;CPET;Borg;6MWT;PRO-BNP;LVEF;Readmission rate HPLP-II |
| KANG TD 2017 [ | RCT | 69±7/68±7 | 44/44 | MT+CR/MT | 6 | LVEF;LVDD;LVDs;MLHFQ;6MWT;PRO-BNP;CTNI; |
| JIN LJ 2019 [ | RCT | 70.03±6.71/69.92±6.63 | 35/35 | MT+CR/MT | 3 | 6MWT;MLHFQ;Readmission rate |
| HUI HP 2020 [ | RCT | 87.3±6.4/86.3±7.8 | 58/54 | MT+CR/MT | 3 | 6MWT;peakSV;peak CO;TPVR;SF-36 |
| HU YH 2020 [ | RCT | 62.53±8.75/63.05±8.54 | 47/47 | MT+CR/MT | 3 | LVEF;LVDD;LVDs |
| FANG KH 2020 [ | RCT | 68.29±4.07/68.56±4.22 | 75/75 | MT+CR/MT | 6 | LVEF;LVDD;LVDs;PRO-BNP;CTNI;SDS;SAS;MLHFQ |
| DING F 2020 [ | RCT | 68.92±4.62/68.47±4.42 | 38/38 | MT+CR/MT | 3 | CD-RISC;MLHFQ;6MWT |
| ZU LFYYKM 2018 [ | RCT | 68.1±6.3/67.5±5.8 | 38/37 | MT+CR/MT | 6 | 6MWT;LVEF;LVDD; BNP |
| Austin 2005 [ | RCT | 71.9±6.3/71.8±6.8 | 100/100 | MT+CR/MT | 2–6 | 6MWT;MLHF;QOL;NYHA;Borg;Readmission rate; Death rate |
| Austin 2008 [ | RCT | 71.9/71.8 | 100/100 | MT+CR/MT | 6–60 | 6MWT;MLHF;QOL; Borg; |
| Dalal 2019 [ | RCT | 69.7±10.9/69.9±11 | 107/109 | MT+CR/MT | 4–12 | QOL;MLHFQ;HADS;SCHFI; ISWT |
| Davidson 2010 [ | RCT | 71.6/73.9 | 53/52 | MT+CR/MT | 3–12 | MLHFQ;HFNAQ;6MWT;NYHA; |
RCT: Randomized controlled trial E: Experimental group C: Control group MT: Medication Therapy CR: CR M: Month LVEF: Left ventricular ejection fraction LVDD: Left ventricular end-diastolic diameter MLHFQ: Minnesota Living with Heart Failure Questionnaire BNP:B natriuretic peptide PRO-BNP: PRO-B natriuretic peptide 6MWT: 6-min walk test LVDs: Left ventricular end-diastolic diameter QOL: Quality of life scale ESES: Exercise self-efficacy Scale CPET: Cardiopulmonary exercise test Borg: Dyspnea score HPLP-II: Health promotes lifestyle peakSV: Peak stroke volume peakCO: Peak Cardiac Output TPVR: Total peripheral vascular resistance SF-36: Short Form-36 Health Status Questionnaire SDS: Self-Rating Depression Scale SAS: Self-rating anxiety scale CD-RISC: CD-Resilience Scale HFNAQ: Heart failure needs Assessment questionnaire SCHFI: Heart failure Self-care Scale ISWT: Incremental shuttle walking test.
Fig 2Risk of bias in the literature.
Fig 3Literature bias risk.
Fig 4Influence of CR on LVEF of patients.
Fig 5Influence of CR on LVEDD of patients.
Fig 6Influence of CR on 6MWT of patients.
Fig 7Influence of CR on Readmission rate of patients.